Prospera Financial Services Inc Makes New Investment in Burning Rock Biotech Limited Sponsored ADR $BNR

Prospera Financial Services Inc purchased a new stake in Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 24,755 shares of the company’s stock, valued at approximately $214,000.

Burning Rock Biotech Stock Performance

BNR opened at $30.08 on Thursday. The business has a 50 day moving average price of $26.91 and a two-hundred day moving average price of $16.59. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.14 and a quick ratio of 2.91. The company has a market capitalization of $323.61 million, a price-to-earnings ratio of -18.12 and a beta of 1.33. Burning Rock Biotech Limited Sponsored ADR has a 1-year low of $2.18 and a 1-year high of $41.72.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Wednesday, January 21st. Wall Street Zen raised Burning Rock Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.